In this study, we compared the first-line treatments of using pembrolizumab-pemetrexed-platinum combination versus bevacizumab-pemetrexed-platinum combination in advanced non-squamous NSCLC without sensitizing EGFR/ALK/ROS1 mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.